There is no single “best” SSRI for panic disorder. The three FDA-approved options, sertraline, fluoxetine, and paroxetine, all reduce panic attack frequency significantly compared to placebo, and clinical guidelines recommend SSRIs as a class rather than singling out one. The right choice depends on your body’s response, your tolerance for specific side effects, and whether you have other conditions being treated at the same time.
That said, the medications do differ in meaningful ways. Some have stronger trial data, some are easier to stop taking, and some cause fewer side effects. Here’s what the evidence actually shows.
FDA-Approved SSRIs for Panic Disorder
Only three SSRIs carry specific FDA approval for treating panic disorder:
- Sertraline (Zoloft) — starting dose of 25 mg/day, target range of 50 to 200 mg
- Fluoxetine (Prozac) — starting dose of 10 mg/day, target range of 20 to 80 mg
- Paroxetine (Paxil) — starting dose of 10 mg/day, target range of 20 to 60 mg
Other SSRIs like escitalopram, citalopram, and fluvoxamine have been studied for panic disorder and are sometimes prescribed off-label, but they don’t have the formal FDA indication. That doesn’t mean they don’t work. It often just means the manufacturer didn’t pursue that specific approval.
The American Psychiatric Association considers SSRIs the best initial medication choice for most people with panic disorder, given their relatively favorable safety and side effect profile compared to older options like tricyclic antidepressants or benzodiazepines.
How the SSRIs Compare in Trials
A large Cochrane review pooling data from thousands of patients found that SSRIs as a class reduce the risk of not responding to treatment by about 25% compared to placebo. Looking at individual medications, the results varied, though direct head-to-head comparisons are limited.
Paroxetine has the most trial data behind it, with nine studies involving nearly 2,500 patients. It showed a 30% reduction in non-response compared to placebo. Fluoxetine showed the largest effect in a single trial of 180 patients, cutting non-response by more than half, but that finding comes from just one study and should be interpreted cautiously. Sertraline fell in the middle, with a 13% reduction in non-response across three trials of about 470 patients.
For remission (not just improvement but getting close to symptom-free), the numbers were broadly similar across medications. Sertraline showed a 24% reduction in failure to remit, paroxetine 18%, and fluoxetine 20%. The differences between them are not large enough to declare a clear winner, especially since these comparisons are indirect, drawn from separate trials rather than studies that tested the drugs against each other.
Tolerability and Side Effects
This is where the medications start to separate more clearly. Paroxetine, despite its strong efficacy data, has a notably less favorable side effect profile. It causes more anticholinergic effects (dry mouth, constipation, drowsiness) and is particularly difficult to stop taking. Discontinuation symptoms like tension, confusion, and nausea occur at significantly higher rates with paroxetine than with other SSRIs. It requires a slow, gradual taper when it’s time to come off.
A meta-analysis of over 25,000 participants across 117 trials found that escitalopram and sertraline had the best tolerability profiles among newer antidepressants, with significantly fewer people dropping out of treatment compared to paroxetine and other options. Escitalopram also produces fewer discontinuation symptoms when stopping treatment.
Fluoxetine has a very long half-life, meaning it stays in your system for weeks after you stop taking it. This is actually an advantage when discontinuing, since it essentially tapers itself. The downside is that it interacts with more medications because of how it’s processed in the liver.
Sertraline tends to sit in a practical sweet spot: solid efficacy data, good tolerability, and fewer drug interactions than fluoxetine or paroxetine. This is one reason many clinicians reach for it first, even though no guideline formally ranks it above the others.
How SSRIs Reduce Panic Attacks
Panic attacks involve a fear circuit in the brain that fires inappropriately. The amygdala, your brain’s threat-detection center, sends alarm signals to other regions that spike your heart rate, flood your body with stress hormones, and accelerate your breathing. In people with panic disorder, this system is overly sensitive, triggering a full fight-or-flight response without a real threat.
SSRIs work by increasing serotonin availability in the brain. Serotonin helps calm the amygdala and strengthen the prefrontal cortex’s ability to regulate emotional responses. Over time, this reduces the amygdala’s hair-trigger reactivity and quiets the downstream cascade of physical symptoms that define a panic attack.
What to Expect in the First Few Weeks
SSRIs don’t work immediately for panic disorder. The therapeutic effect typically begins to emerge after two to four weeks, with continued improvement through weeks eight to twelve. Some people need a full 12 weeks on an adequate dose before they can tell whether a given medication is working.
The first one to two weeks can be uncomfortable. SSRIs sometimes cause a temporary increase in anxiety, restlessness, or agitation when you first start taking them. This “activation” effect can be particularly unsettling if you already have panic disorder, since it can feel like your symptoms are getting worse before they get better. This is a known phenomenon that usually resolves within the first few weeks. Starting at a low dose and increasing gradually helps minimize it.
Roughly 59% of people with panic disorder respond to SSRI treatment, compared to about 46% on placebo. That means SSRIs genuinely help, but they’re not a guarantee. If the first one doesn’t work after an adequate trial of 8 to 12 weeks at a therapeutic dose, switching to a different SSRI or another class of medication is a reasonable next step.
Staying On Treatment and Relapse Risk
One of the most important decisions with SSRIs isn’t which one to start but how long to stay on it. Among people who achieved remission and then stopped their antidepressant (switched to placebo in controlled trials), about 36% relapsed. For those who continued their medication, the relapse rate was only 16%. That’s a meaningful difference.
The risk climbs higher if you have other conditions alongside panic disorder. In one trial, people with two or more additional diagnoses who stopped medication had relapse rates as high as 77%, compared to 33% for those without comorbid conditions.
Most guidelines recommend continuing treatment for at least a year after symptoms are well controlled before considering a taper. When it is time to stop, doing so gradually over weeks or months is important, particularly with paroxetine, which causes the most withdrawal symptoms of the group.
How to Think About Choosing
If you’re trying to figure out which SSRI to ask about or expect your prescriber to suggest, here’s a practical framework. Sertraline is often a strong default choice because it balances good efficacy with tolerability and manageable drug interactions. Fluoxetine is a reasonable alternative, especially if you’re concerned about discontinuation problems down the road, since its long half-life makes tapering easier. Paroxetine is effective but carries more side effects and a harder discontinuation process, which makes it a less common first choice despite having the most clinical trial data. Escitalopram, while not FDA-approved specifically for panic disorder, has strong tolerability data and is frequently prescribed off-label.
The reality is that individual response to SSRIs varies in ways that can’t be predicted in advance. Two people with identical panic disorder severity may respond completely differently to the same medication. Finding the right fit sometimes requires trying more than one, and that process, while frustrating, is normal and expected.